Literature DB >> 10975510

Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients.

S Couban1, H A Messner, P Andreou, B Egan, S Price, L Tinker, J Meharchand, D L Forrest, J Lipton.   

Abstract

We studied whether a short course of granulocyte colony-stimulating factor (G-CSF) administered to normal donors immediately before bone marrow (BM) harvest would shorten time to neutrophil and platelet engraftment in matched related allogeneic BM recipients. Twenty-nine normal donors received 4 consecutive daily subcutaneous injections of G-CSF (median dose, 12.1 microg/kg per day; range, 9.6-15.7 microg/kg per day) immediately before BM harvest. Donors tolerated G-CSF well, with only mild myalgias and arthralgias, and BM was easy to aspirate. The BM harvest contained a median of 5.3 x 10(8) white blood cells (WBCs)/kg (range, 3.1-11.1 x 10(8) WBCs/kg) and 2.5 x 10(6) CD34+ cells per kg (range, 1.5-7.3 x 10(6) CD34+ cells per kg). Median times to neutrophil (18 days [range, 11-30 days] versus 22 days [range, 16-36 days]; P = .05) and platelet (22 days [range, 15-55 days] versus 27 days [range, 18-46 days]; P = .04) engraftment were statistically shorter than those of historical control subjects whose donors had not received G-CSF before BM harvest. However, secondary engraftment-dependent outcomes including red blood cell and platelet transfusions, febrile days, days on antibiotics, days from transplant to hospital discharge, and days in hospital during the first 60 days after transplant were not statistically different from historical control subjects. We conclude that G-CSF administered to normal donors immediately before harvest facilitates BM aspiration, increases the WBC content of the harvest, and hastens neutrophil and platelet engraftment compared with historical control subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975510     DOI: 10.1016/s1083-8791(00)70033-4

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

Authors:  Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 2.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 3.  G-CSF-primed BM for allogeneic SCT: revisited.

Authors:  I Pessach; I Resnick; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

Review 4.  Allogeneic transplantation: peripheral blood vs. bone marrow.

Authors:  William I Bensinger
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

Review 5.  Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Authors:  Uday Deotare; Dennis Dong Hwan Kim; Jeffrey H Lipton
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

6.  Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia.

Authors:  Yuhang Li; Min Jiang; Chen Xu; Jianlin Chen; Botao Li; Jun Wang; Jiangwei Hu; Hongmei Ning; Hu Chen; Shuiping Chen; Liangding Hu
Journal:  Chin Med J (Engl)       Date:  2015-01-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.